Market Overview

Benzinga's Top Pre-Market Losers

Share:
Related NAVB
Macrophage Therapeutics Reports Data Demonstrating a Manocept™ Drug Conjugate Induces Apoptosis in CD206 Positive Kaposi's Sarcoma and Tumor Associated Macrophages
Navidea Announces Clinical Data for Manocept Shows Agent Localizes in Multiple KS Lesions
Navidea Biopharma reports Q2 results (Seeking Alpha)
Related
Palo Alto Networks CEO On The Changing Perception Toward Cybersecurity
So You Want To Play The Cybersecurity Sector Right Now...
Check Point Doesn't Need To Feel Insecure (Seeking Alpha)

Navidea Biopharmaceuticals (AMEX: NAVB) dipped 33.33% to $2.34 in the pre-market session. Navidea Biopharmaceuticals received a Complete Response Letter from the Food and Drug Administration regarding its New Drug Application for Lymphoseek®.

United Natural Foods (NASDAQ: UNFI) moved down 6.17% to $56.70 in the pre-market session. United Natural Foods reported a 46% rise in its fourth-quarter profit.

Palo Alto Networks (NASDAQ: PANW) dipped 5.92% to $67.50 in the pre-market session. Palo Alto Networks posted a narrower fiscal fourth-quarter loss.

Sequenom (NASDAQ: SQNM) shares fell 5.37% to $3.70 in the pre-market trading. Sequenom intends to offer $100.0 million aggregate principal amount of Convertible Senior Notes due 2017 in a private offering.

Posted-In: Top Pre-Market LosersNews Movers & Shakers Pre-Market Outlook Markets

 

Related Articles (NAVB + PANW)

Get Benzinga's Newsletters